CN110691588A - 用于持续递送生物活性分子的矿物质涂覆微粒 - Google Patents

用于持续递送生物活性分子的矿物质涂覆微粒 Download PDF

Info

Publication number
CN110691588A
CN110691588A CN201880036493.0A CN201880036493A CN110691588A CN 110691588 A CN110691588 A CN 110691588A CN 201880036493 A CN201880036493 A CN 201880036493A CN 110691588 A CN110691588 A CN 110691588A
Authority
CN
China
Prior art keywords
mineral
active agent
antagonist
coating
mineral coating
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201880036493.0A
Other languages
English (en)
Chinese (zh)
Inventor
W·墨菲
A·克莱门茨
C·张伯伦
R·范德比
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wisconsin Alumni Research Foundation
Original Assignee
Wisconsin Alumni Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wisconsin Alumni Research Foundation filed Critical Wisconsin Alumni Research Foundation
Publication of CN110691588A publication Critical patent/CN110691588A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6923—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being an inorganic particle, e.g. ceramic particles, silica particles, ferrite or synsorb
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Ceramic Engineering (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CN201880036493.0A 2017-04-03 2018-04-03 用于持续递送生物活性分子的矿物质涂覆微粒 Pending CN110691588A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762480710P 2017-04-03 2017-04-03
US62/480,710 2017-04-03
PCT/US2018/025913 WO2018187344A1 (en) 2017-04-03 2018-04-03 Mineral coated microparticles for sustained delivery of biologically active molecules

Publications (1)

Publication Number Publication Date
CN110691588A true CN110691588A (zh) 2020-01-14

Family

ID=63712804

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880036493.0A Pending CN110691588A (zh) 2017-04-03 2018-04-03 用于持续递送生物活性分子的矿物质涂覆微粒

Country Status (10)

Country Link
US (2) US12465654B2 (https=)
EP (1) EP3606512A4 (https=)
JP (1) JP7170031B2 (https=)
KR (1) KR20190130643A (https=)
CN (1) CN110691588A (https=)
AU (1) AU2018249816B2 (https=)
BR (1) BR112019020373A2 (https=)
CA (1) CA3058802A1 (https=)
IL (1) IL269607A (https=)
WO (1) WO2018187344A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114917364A (zh) * 2022-05-12 2022-08-19 云南大学附属医院 一种携IL-8和Anakinra双配体靶向纳米微泡的制备方法

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018187344A1 (en) 2017-04-03 2018-10-11 Wisconsin Alumni Research Foundation Mineral coated microparticles for sustained delivery of biologically active molecules
WO2022051247A1 (en) * 2020-09-01 2022-03-10 Dianomi Therapeutics, Inc. Methods for treating or preventing inflammatory events
DE102020129648A1 (de) * 2020-11-10 2022-05-12 Leopold MTX GmbH Pharmazeutische zusammensetzung
WO2024102801A2 (en) * 2022-11-09 2024-05-16 Wisconsin Alumni Research Foundation Mineral-coated iron oxide microparticles and use of same including use for immunomodulation

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1541100A (zh) * 2001-06-08 2004-10-27 用于骨诱导蛋白的磷酸钙传递载体
CN1964737A (zh) * 2004-06-04 2007-05-16 瑞泽恩制药公司 利用il－1拮抗剂治疗自身炎症性疾病的方法
US20100015049A1 (en) * 2008-07-16 2010-01-21 Warsaw Orthopedic, Inc. Methods and compositions for treating postoperative pain comprising nonsteroidal anti-inflammatory agents
WO2010036919A1 (en) * 2008-09-25 2010-04-01 Tissue Regeneration Systems, Inc. Mineral-coated microspheres

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5075222A (en) 1988-05-27 1991-12-24 Synergen, Inc. Interleukin-1 inhibitors
JP2003212756A (ja) * 2002-01-21 2003-07-30 Olympus Optical Co Ltd 薬剤徐放剤
US7655758B2 (en) * 2004-08-17 2010-02-02 Regeneron Pharmaceuticals, Inc. Stable liquid IL-1 antagonist formulations
US7473678B2 (en) * 2004-10-14 2009-01-06 Biomimetic Therapeutics, Inc. Platelet-derived growth factor compositions and methods of use thereof
MX373000B (es) * 2005-09-14 2020-05-21 Mannkind Corp Metodo para formulacion de farmaco basado en el aumento de la afinidad de agentes activos hacia las superficies de microparticulas cristalinas.
WO2008041704A1 (fr) * 2006-10-02 2008-04-10 National Institute For Materials Science Préparation à libération contrôlée
US20100143439A1 (en) * 2007-04-16 2010-06-10 University Of Toledo Hybrid Biomimetic Particles, Methods of Making Same and Uses Therefor
US8470360B2 (en) 2008-04-18 2013-06-25 Warsaw Orthopedic, Inc. Drug depots having different release profiles for reducing, preventing or treating pain and inflammation
US20090111763A1 (en) * 2007-10-26 2009-04-30 Celonova Biosciences, Inc. Loadable polymeric particles for bone augmentation and methods of preparing and using the same
ES2603961T3 (es) 2008-02-29 2017-03-02 Smith & Nephew, Inc. Recubrimiento de gradiente para aplicaciones biomédicas
US20160017368A1 (en) * 2013-02-19 2016-01-21 Wisconsin Alumni Research Foundation Inorganic coatings for the enhancement of chemical transfection
JP6827960B2 (ja) 2015-03-03 2021-02-10 ティーアールエス ホールディングス リミテッド ライアビリティ カンパニー コーティングスキャフォールド
SG11201707663SA (en) 2015-04-17 2017-11-29 Curevac Ag Lyophilization of rna
WO2018187344A1 (en) 2017-04-03 2018-10-11 Wisconsin Alumni Research Foundation Mineral coated microparticles for sustained delivery of biologically active molecules
US11628227B2 (en) 2017-07-05 2023-04-18 Wisconsin Alumni Research Foundation Mineral coated microparticles for gene delivery in chronic wound therapy
CA3068917A1 (en) 2017-07-05 2019-01-10 Wisconsin Alumni Research Foundation Mineral coated microparticles for co-delivery of anti-inflammatory molecules with nucleic acids to improve gene delivery outcomes
EP3556728A1 (en) 2018-04-16 2019-10-23 Croda Denmark A/S Organically modified mineral micro-particles, methods of preparing the same and uses thereof
US20190358344A1 (en) 2018-05-23 2019-11-28 Dianomi Therapeutics, Inc. Mineral coated microparticles for sustained delivery of steroids
US20240325596A1 (en) 2021-11-09 2024-10-03 Wisconsin Alumni Research Foundation Mineral-coated substrates for stabilization of rna-based therapeutic compositions

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1541100A (zh) * 2001-06-08 2004-10-27 用于骨诱导蛋白的磷酸钙传递载体
CN1964737A (zh) * 2004-06-04 2007-05-16 瑞泽恩制药公司 利用il－1拮抗剂治疗自身炎症性疾病的方法
US20100015049A1 (en) * 2008-07-16 2010-01-21 Warsaw Orthopedic, Inc. Methods and compositions for treating postoperative pain comprising nonsteroidal anti-inflammatory agents
WO2010036919A1 (en) * 2008-09-25 2010-04-01 Tissue Regeneration Systems, Inc. Mineral-coated microspheres

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
PHUONG N. DANG等: ""Guiding Chondrogenesis and Osteogenesis with Mineral-Coated Hydroxyapatite and BMP 2 Incorporated within High-Density hMSC Aggregates for Bone Regeneration"", 《ACS BIOMATER. SCI. ENG.》 *
REBECCA L.ATTRIDGE等: "《内科学临床治疗手册》", 31 January 2016, 人民军医出版社 *
XIAOHUA YU等: ""Multilayered Inorganic Microparticles for Tunable Dual Growth Factor Delivery"", 《ADV. FUNCT. MATER.》 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114917364A (zh) * 2022-05-12 2022-08-19 云南大学附属医院 一种携IL-8和Anakinra双配体靶向纳米微泡的制备方法

Also Published As

Publication number Publication date
AU2018249816B2 (en) 2025-04-17
AU2018249816A1 (en) 2019-10-17
EP3606512A1 (en) 2020-02-12
WO2018187344A1 (en) 2018-10-11
US20260041786A1 (en) 2026-02-12
CA3058802A1 (en) 2018-10-11
BR112019020373A2 (pt) 2020-04-28
US12465654B2 (en) 2025-11-11
US20200164087A1 (en) 2020-05-28
JP7170031B2 (ja) 2022-11-11
IL269607A (en) 2019-11-28
KR20190130643A (ko) 2019-11-22
JP2020513033A (ja) 2020-04-30
EP3606512A4 (en) 2021-01-13

Similar Documents

Publication Publication Date Title
US20260041786A1 (en) Mineral coated microparticles for sustained delivery of biologically active molecules
JP7212653B2 (ja) 抗炎症剤としてのｐｒｇ４の使用
AU2020203367A1 (en) Compositions and methods for treating lung diseases and lung injury
US11779542B2 (en) Mineral coated microparticles for co-delivery of anti-inflammatory molecules with nucleic acids to improve gene delivery outcomes
EP2941243A1 (en) Surface binding of nanoparticle based drug delivery to tissue
JP2020511415A (ja) 線維症の処置のためのインターフェロン−ラムダの医学的使用
Yang et al. Synergy of polydopamine nanovaccine and endostar alginate hydrogel for improving antitumor immune responses against colon tumor
WO2009097704A1 (en) Antigen-binding polypeptides against cartilage degeneration
CA3235778A1 (en) Methods of use and administration of encapsulated cells
JP2015524402A (ja) 創傷治療用の薬剤
Watanabe et al. Local administration and enhanced release of bone metabolic antibodies from hydroxyapatite/chondroitin sulfate nanocomposite microparticles using zinc cations
Ubhe IL-1 receptor antagonist: etiological and drug delivery systems overview
HK40014557A (en) Mineral coated microparticles for sustained delivery of biologically active molecules
WO2022051247A1 (en) Methods for treating or preventing inflammatory events
TWI395592B (zh) 由聚乳酸－甘醇酸（ｐｏｌｙ（ｌａｃｔｉｃ－ｃｏ－ｇｌｙｃｏｌｉｃ ａｃｉｄ））微小球控制釋放副甲狀腺素之方法
EP4271412A1 (en) Extended local release of antibodies
Riemann et al. Active nanoparticle targeting of MUC5AC ameliorates therapeutic outcome in experimental colitis
Hao et al. Drug-free mesenchymal stem cell-mimicking nanodecoys suppress inflammation and attenuate new bone formation in ankylosing spondylitis
Wang et al. Exploring the multi-repair effects of advanced biomimetic rapamycin nanoparticles on cerebral ischemia-reperfusion injury
Zhang et al. Cationic microparticles inhibit local sterile inflammation in tissue injuries
WO2023027132A1 (ja) 骨代謝細胞調節剤及びその利用
WO2022146925A1 (en) Extended local release of antibodies
CN120344255A (zh) 使用基于脂质结合蛋白的复合物治疗过度炎性病症的方法
Clements Microparticles for Sustained Systemic or Local Delivery of Active Interleukin-1 Receptor Antagonist
Egashira et al. Novel biological strategies for treatment of wear

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40014557

Country of ref document: HK